Pharmaron Beijing Co., Ltd.
300759
Kedudukan dalam Saham
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Harga Saham
$5.58
Modal Pasaran
$8.24B
Perubahan (1 hari)
-3.77%
Perubahan (1 tahun)
28.36%
Negara
CN
Perdagangan Pharmaron Beijing Co., Ltd. (300759)
Kategori
Healthcare
Hasil untuk Pharmaron Beijing Co., Ltd. (300759)
Hasil pada Jun 2026 TTM: $2.28B
Menurut laporan kewangan terkini daripada Pharmaron Beijing Co., Ltd., hasil semasa syarikat (TTM) ialah $2.28B. Pada tahun 2024, syarikat memperoleh hasil sebanyak $1.68B peningkatan berbanding hasil pada tahun 2023 iaitu $1.63B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Pharmaron Beijing Co., Ltd. dari 2014 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $2.28B | 12.93% |
| 2025 | $2.01B | 19.79% |
| 2024 | $1.68B | 3.18% |
| 2023 | $1.63B | 9.52% |
| 2022 | $1.49B | 27.08% |
| 2021 | $1.17B | 49.03% |
| 2020 | $785.83M | 45.64% |
| 2019 | $539.57M | 27.62% |
| 2018 | $422.78M | 19.90% |
| 2017 | $352.61M | 49.80% |
| 2016 | $235.38M | 35.50% |
| 2015 | $173.71M | 36.12% |
| 2014 | $127.61M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 454.89% |
US
|
|
| $2.23B | -2.07% |
US
|
|
| $15.74B | 592.03% |
AU
|
|
| $10.11B | 344.41% |
BE
|
|
| $6.02B | 164.66% |
NL
|
